STOCK TITAN

Chinook Therapeutics Inc - KDNY STOCK NEWS

Welcome to our dedicated news page for Chinook Therapeutics (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chinook Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chinook Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
offering
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
offering
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
earnings
Chinook Therapeutics Inc

Nasdaq:KDNY

KDNY Rankings

KDNY Stock Data

2.71B
61.16M
2.19%
96.71%
4.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley

About KDNY

chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.